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its Rationality.
Methods: The study enrolled all out-patients prescriptions for the
treatment of osteoarthritis in Peking University People's Hospital in
2012. Statistical method was applied to analyze the characters of the
treatment for OA, and the differences of the choice of medications
caused by different clinical departments.
Results: A total of 67382 prescriptions involving 25410 osteoarthritis
out- patients were enrolled in this study. The incidence of OA- related
visits to the hospital was 2.6 times per year per person. 51 medications
were given, categorized into 8 groups according to 2008 OARSI hip and
knee osteoarthritis recommendations:①topical NSAIDs and capsaicin;
②acetaminophen; ③NSAIDs; ④weak opioids; ⑤intra-articular(IA)
injections; ⑥glucosamine; ⑦anti-osteoporosis drugs;⑧traditional
Chinese medicine(TCM). As many as 23 species of TCM were involved,
seconded by anti-osteoporosis drugs(9 species). Among all the drugs,
TCM was the most commonly prescribed(61.3%), seconded by glucos-
amine(50.6%). The study mainly involved rheumatology department,
orthopedics department, pain management department, and depart-
ment of traditional Chinese medicine. Different specialists prescribed
differently, while rheumatologists may prefer NSAIDs(24.6%) and glu-
cosamine(78.9%) more, orthopedics prefer NSAIDs(28.3%), glucos-
amine(60.4%) and TCM(66.1%), doctors from pain management
department may give more weak opioids(17.7%), glucosamine(60.4%)
and IA agents(86.2%), and traditional Chinese doctors mainly prescribe
traditional Chinese medicine(90.3%). 83.3% of all prescriptions include
oral medications, 41.5% include topical agent. Rheumatologists and
orthopedics give more oral medications, doctors from pain manage-
ment department prefer IA agents. Doctors from traditional Chinese
medicine department use more topical agent.
Conclusions: Physicians in China prefer to use glucosamine and tradi-
tional Chinese medicine to treat OA, which is lack of clear guidelines.
Compared with the physicians from the traditional Chinese medine
department and the pain management department, rheumatologists
and orthopedics treatment OA based on guidelines more.
Therapy: Biological
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PHASE 1 STUDIES OF ANTI-INTERLEUKIN-1 DUAL-VARIABLE
DOMAIN IMMUNOGLOBULIN IN HEALTHY SUBJECTS AND PATIENTS
WITH OSTEOARTHRITIS
S.X. Wang y, W. Liu y, P. Jiang y, M. Okun y, R.A. Preston z, C.J. Lozada z,
D. Carter y, J.K. Medema y. yAbbVie Inc, North Chicago, IL, USA; zMiller
Sch. of Med., Univ. of Miami, Miami, FL, USA
Purpose: Interleukin (IL)-1 is a potent catabolic cytokine that plays an
important role in the pathogenesis and progression of osteoarthritis
(OA). Preclinical proof of concept for simultaneous inhibition of IL-1a
and IL-1bwas demonstrated by both cartilage protection and increased
tolerance to mechanical nociceptive pain. Two phase 1 clinical trials
investigated the use of a novel human dual-variable
domainimmunoglobulin (DVD-Ig™) simultaneously targeting IL-1a
and IL-1b (ABT-981).
Methods: ABT-981 was evaluated in a randomized, double-blind, single
ascending dose (SAD), placebo-controlled trial in 56 healthy subjects
and in a randomized, double-blind, multiple ascending dose (MAD),
placebo-controlled trial in 36 patients with mild to moderate knee OA
(NCT01668511). In the SAD trial, each cohort received a single intra-
venous (IV) or subcutaneous (SC) dose of ABT-981 (0.3, 1, 3, and 10 mg/
kg IV or 0.3, 1, and 3mg/kg SC) or placebo in a 6:2 ratio. In theMAD trial,
cohorts 1-3 received ABT-981 (0.3, 1, or 3 mg/kg) or placebo in a 7:2
ratio every 2 weeks (EOW) for 4 SC injections total, and cohort 4
received ABT-981 (3 mg/kg) or placebo in a 7:2 ratio every 4 weeks
(E4W) for 3 SC injections total. Safety, tolerability, pharmacokinetics
(PK), anti-drug antibodies (ADAs), and biomarkers were assessed
through day 85 in the SAD trial and through day 113 for the ﬁrst 3
cohorts and through day 127 for the fourth cohort in the MAD trial. In
the MAD trial, a panel of serum/urine biomarkers of target engagement,
inﬂammation and joint degradation were compared between ABT-981-
treated and placebo groups from day 1 to 57.
Results: The incidence of adverse events (AEs) was similar with single-
dose ABT-981 vs placebo via IV (66.7% vs 50.0%) or SC (55.6% vs 66.7%)
routes and with multiple SC doses of ABT-981 vs placebo (53.6% vs62.5%). The majority of AEs were mild or moderate and considered not
or probably not related to study drug. The most common AE with ABT-
981 vs placebo was diarrhea via IV (20.8% vs 12.5%) and headache via SC
(22.2% vs 0%) in the SAD trial, and injection-site reaction (17.9% vs 0%) in
the MAD trial. No infusion reactions or injection-site reactions occurred
in the SAD trial. In the MAD trial, absolute neutrophil count (ANC)
decreased dose-dependently with ABT-981 dosing, starting at 48 hours
and reaching nadir by 14 days, with lowest ANC values (2.1-2.3/mm3)
observed with 3 mg/kg. Only 1 patient had a transient grade 2 neu-
tropenia after 1 dose in the 3 mg/kg EOW group, which was considered
possibly study-drug related, along with a serious AE of grade 3 bron-
chitis/viral syndrome that was also considered possibly study-drug
related. ABT-981 Cmax and AUC increased in a dose-proportional
manner after single doses of 0.3-10 mg/kg IV or 0.3-3 mg/kg SC and
multiple doses of 0.3-3 mg/kg SC EOW. Estimated relative bioavail-
ability after SC administration was 46%. Following EOW dosing, accu-
mulation in AUCt was approximately 2-fold. Mean terminal half-life
ranged from 10-13 days. No apparent ADA effect on ABT-981 PK was
observed. In the MAD trial, ABT-981 at all 3 doses signiﬁcantly reduced
serum levels of high-sensitivity C-reactive protein (hsCRP; P<0.05),
matrix metalloproteinase (MMP)-degraded type 1 collagen (C1M;
P<0.05 at 1 and 3 mg/kg ), IL-1a (P<0.001; Figure), and IL-1b (P<0.001;
Figure). Serum concentrations of MMP-degraded type 3 collagen (C3M;
1 and 3 mg/kg) and MMP-degraded CRP (CRPM; 3 mg/kg) demon-
strated decreasing trends (0.05<P<0.1) with ABT-981 treatment but did
not reach statistical signiﬁcance. These trends suggest that ABT-981
engaged with IL-1a and IL-1b targets and elicited an anti-inﬂammatory
response in patients with knee OA.
Conclusions: The results of these phase 1 trials demonstrate that ABT-
981 was well tolerated and had dose-proportional PK in healthy sub-
jects and patients with knee OA. The similar safety proﬁles between
ABT-981 and placebo support phase 2 investigation of ABT-981 in
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A399patients with OA. Through simultaneous inhibition of IL-1a and IL-1b in
patients with OA, ABT-981 signiﬁcantly reduced serum hsCRP levels,
indicating a reduction in systemic inﬂammation, and C1M levels, indi-
cating a dampening of inﬂammation-mediated joint destruction.
Additionally, the observed serum C3M and CRPM decreases suggest that
ABT-981 may ameliorate inﬂammation-mediated tissue destruction
and chronic tissue inﬂammation with long-term administration in
patients with inﬂammation-driven OA.
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EFFECTS OF EXOSOMES UPON THE METABOLIC ACTIVITIES OF
HUMAN OSTEOARTHRITIC ARTICULAR CARTILAGE IN SITU
A. Rey-Rico y, J. Reinecke z, P. Wehling z, M. Cucchiarini y, H. Madry y.
y Saarland Univ., Homburg, Germany; zOrthogen, Dusseldorf, Germany
Purpose: Exosomes are small nanosized extracellular membrane vesi-
cles produced within multivesicular bodies of the late endocytic com-
partment of hematopoietic and non-hematopoietic cells. Exosomes
have immunoregulatory activities in animal models of inﬂammatory
and autoimmune disease. Osteoarthritis (OA) is mainly characterized by
the degradation of the cartilaginous extracellular matrix (ECM),
resulting in a progressive loss of the articular cartilage. The cascade of
proinﬂammatory and catabolic events is primarily induced by inter-
leukin 1 beta (IL-1b) that ultimately leads to the release of ECM mole-
cules like proteoglycans. Whether exosomes are of value for the
treatment of OA remains, however, unclear. Here, we evaluated the
possible early protective versus suppressive effects of exosomes on the
release and contents of glycosaminoglycans (GAG) in human OA carti-
lage explants treated (or not) with IL-1b, either concomitantly or
sequentially, and relative to the application of autologous conditioned
serum (ACS), a component used in OA patients.
Methods: Human OA cartilage explants (Mankin score ¼ 7-9) were
obtained from patients undergoing total knee arthroplasty and placed
in serum-free medium. In order to study the component-induced pro-
tective, suppressive, or deleterious effects on cartilage metabolic pro-
cesses, the following experimental groups were evaluated: Group 1:
explants treated with total serum, serum without exosomes (ﬁnal
concentration: 10%) and exosomes (15 ml), with untreated explants
cultured in DMEM serving as controls; Group 2: explants treated con-
comitantly with IL-1b and with total serum, serum without exosomes
and exosomes (similar amounts as for group 1), respectively, with
controls using solely IL-1b in DMEM; Group 3: explants treated
sequentially with IL-1b for 6 h and next with total serum, serum
without exosomes and exosomes (see group 1), respectively, with
controls using solely IL-1b in DMEM. IL-1b was applied at 10 ng/ml
where indicated. Exosomal protein contents administered in the
experiments were of 78.3 ± 11.3 mg. All the groups were further
maintained for 48 h. GAG contents and released were monitored by
DMMB assay in the explants versus culture supernatants, respectively.
Cytotoxicity of the compounds was evaluated by LDH assay using the
culture medium of the explants. Each condition was performed in
quadruplicate in four independent experiments. The t-test was
employed with P  0.05 considered statistically signiﬁcant.
Results: No cytotoxic effects were associated with the various com-
pounds. Cell viability decreased of ~ 65% only with serum and IL-1b. All
compounds reduced the amounts of GAG released in the culture
medium in the untreated conditions (group 1), with the exception of
serum treatment. Both concomitant and sequential administration of
IL-1b with the compounds (groups 2 and 3, respectively) decreased the
amounts of GAG released compared with the controls. When analyzing
the % of GAG remaining in the explants or released in the medium, all
the compounds prevented the release of GAG compared with the con-
trols, both in the untreated conditions (group 1) and when providing
them together with IL-1b (group 2). Similarly, all the compounds
moderated the effects of IL-1b in a sequential setting (group 3),
although only the condition of serum without exosomes was statisti-
cally signiﬁcant compared with the DMEM control.
Conclusions: Exosomes can modulate GAG release in human OA car-
tilage, an effect particularly pronounced in the presence of proin-
ﬂammatory IL-1b. Independently of the presence of exosomes, ACS
exerts similar effects. A signiﬁcant protective effect of all treatment
groups was also noted on the GAG contents in the samples compared
with the control when provided with IL-1b. This work shows the the
value of exosomes to protect human OA cartilage from GAG loss of,
avoiding the use of less deﬁned ACS. Experiments are ongoing toevaluate dose-dependent effects of exosomes, including at later time
points.
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CONCENTRATIONS OF CYTOKINES, MATRIX METALLOPROTEINASES,
AND TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES IN
AUTOLOGOUS CONDITIONED SERUM FROM HORSES WITH DISTAL
INTERPHALANGEAL JOINT OSTEOARTHRITIS
D.M. Tatarniuk y, D.M. Groschen y, K.A. Merritt z, M.C. Maher y,
N.S. Ernst y, M.P. Brown z, T.N. Trumble y. yUniv. of Minnesota e Coll. of
Vet. Med., St. Paul, MN, USA; zUniv. of Florida e Coll. of Vet. Med.,
Gainesville, FL, USA
Purpose: Autologous conditioned serum (ACS) is a novel intra-articular
treatment for osteoarthritis (OA). Processed from the patient’s own
blood, monocytes are activated by exposure to borosilicate beads during
incubation, resulting in “conditioned” serum that has increased con-
centrations of interleukin-1 receptor antagonist protein (IL-1ra), an
anti-inﬂammatory cytokine. Although commonly used, scientiﬁc
knowledge is limited regarding ACS composition and variability
between individuals. The purpose of this study was to determine
cytokine, matrix metalloproteinase (MMP), and tissue inhibitor of MMP
(TIMPs) concentrations in newly processed and freeze/thawed con-
ditioned serum, compared to baseline serum samples that were either
unconditioned or incubated.
Methods: Eleven horses with distal interphalangeal joint OA had 50mls
of blood aspirated directly into an ACS syringe containing borosilicate
beads (IRAP™ II System, Arthrex Vet Systems), incubated at 37C for ~20
hours, and centrifuged for 10 minutes at 2500xg. This conditioned
serum (ACS) was aliquoted into 5ml doses for 3 weekly treatments into
the joint (Days 0, 7,&14), with any remaining ACS further aliquoted and
frozen at -80C for future analysis. Day 7 & 14 doses were stored frozen
(-20C) and thawed prior to administration, with 1ml aliquoted and
refrozen at -80C to assess effect of freeze-thaw (FT) on ACS composition.
As a control, an additional 20ml of blood was simultaneously collected
with 10mls centrifuged/decanted within 1-hr following venipuncture
(baseline control), and 10mls centrifuged/decanted following incuba-
tion for ~20 hours (unconditioned), similar to ACS samples. Baseline
control, unconditioned/incubated controls (20 hr), fresh conditioned
(ACS) and freeze-thawed (FT ACS) serumwas evaluated using ELISA (IL-
ra) or multiplex assays (R&D Systems) to evaluate cytokines (IL-1ra, IL-
1b, TNFa, IL-4, IL-6, IL-8, IL-10), MMP-1, -3, -9, and -13, and TIMP-1, -2,
-3, and -4 concentrations. All samples were run in duplicate or triplicate
at appropriate dilutions. Serum concentrations were compared using
one-way ANOVA, with Tukey’s post-hoc multiple comparisons
(p<0.05).
Results: ACS IL-1ra concentrations were signiﬁcantly higher than
baseline control serum, but not signiﬁcantly different from 20 hr
incubated control serum (Fig 1). ACS IL-4 and IL-8 concentrations were
signiﬁcantly lower than unconditioned and incubated serum (Fig 1).
ACS IL-6 concentrations were signiﬁcantly lower than in incubated
serum (Fig 1). MMP-1& -9 in ACS was signiﬁcantly higher than baseline
controls. There were no differences in TIMP concentrations between
groups. Marked variability existed between individual horses for all
analytes evaluated. Speciﬁcally, mean (±SD) IL-1ra concentration was
6585pg/ml (±2750pg/ml) with a coefﬁcient of variation (CV) of 41.76%.
Thirteen of 15 measured analytes had a CV >20%. No differences were
noted between fresh ACS and FT ACS samples from day 7& 14. However,
most measured analytes demonstrated a decrease in concentration
(~10%) in FT samples compared to fresh ACS.
Conclusions: Results conﬁrm that ACS signiﬁcantly elevates IL-1ra
compared to baseline. However, 20 hr incubated serum appears to have
IL-1ra concentrations similar to ACS. This may suggest that serum does
not need to be conditioned with borosilicate beads to increase IL-1ra
concentrations. However, our results suggest that the beads may be
beneﬁcial because ACS had signiﬁcantly lower IL-4, IL-6, & IL-8 con-
centrations than the 20 hr incubated control. Thus, exposure of serum
to beads may suppress production of some cytokines. The clinical sig-
niﬁcance of this ﬁnding is unclear. Increased MMP-1 & MMP-9 in ACS
may promote a catabolic environment within articular cartilage, which
would be undesirable. Marked variability in ACS composition between
individual horses may contribute to the often unpredictable response to
therapy. In clinical practice, excess ACS is frozen and thawed to facilitate
serial administration. Our results indicate that ACS undergoing a freeze-
thaw cycle is similar to original (fresh) ACS product.
